Abstract
The present study aims to characterize the genetic predisposition for the development of Mesoamerican Nephropathy (MeN) in patients from Panama. A Whole Exome Sequencing approach was performed in patients diagnosed with MeN using the criteria of the Pan American Health Organisation (PAHO), and clinical variables were analysed in all patients and in a group of exposed healthy donors and a group of non-exposed healthy donors. We found a variant located in the APOE gene (rs429358 c.388T>C p.(Cys130Arg), identified in 26% (16/61) of patients with MeN, that corresponds to the APOE4 haplotype. In the group of patients with the APOE4 haplotype we have identified that uric acid is elevated when compared to the group of patients without the haplotype. To the best of our knowledge, this is the first study to find variants in the APOE gene as an important genetic risk factor in patients with MeN. These patients have higher hyperuricemia than patients without the variant, which would indicate an important role of uric acid in the pathophysiology of the disease, suggesting the potential use of uric acid-lowering drugs in these patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Secretaria Nacional de Ciencia, Tecnologia e Innovacion, SENACYT, Panama, project IOMS19-013.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Interinstitutional Ethics Committee of the Social Security Fund and the National Directorate for Teaching and Research (Human Ethics approval No. CIEI-CSS-M-181-12019). No further administrative permissions were needed to access the raw data used in this study. The data used in this study were anonymized before use.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data generated or analysed during this study are included in this published article.
